Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TRIB | 6-K | bearish | 7/10 | Trinity Biotech filed a 6-K providing a business update and disclosing receipt of a Nasdaq delisting determination lette | Aug 28, 2026 |
| JUNS | 8-K | bearish | 8/10 | Jupiter Neurosciences received a delisting notice from Nasdaq on August 27, 2026, for failing to maintain the minimum $3 | Aug 28, 2026 |
| ATTO | 144, CLUSTER | neutral | 3/10 | Goldman Sachs Group Inc., a former 10% owner of Attovia Therapeutics, filed a Form 144 notice of intent to sell 105,807 | Aug 28, 2026 |
| BOLD | 425, 8-K | neutral | 4/10 | Boundless Bio (BOLD) and Serapha Bio entered into Amendment No. 1 to their Merger Agreement, making technical clarificat | Aug 28, 2026 |
| SPRO | 8-K | bearish | 7/10 | Spero Therapeutics entered into a new at-the-market (ATM) equity offering agreement with Jefferies LLC for up to $100M i | Aug 28, 2026 |
| SGMOQ | 8-K | bearish | 9/10 | Sangamo Therapeutics, already in Chapter 11 bankruptcy, has entered into an asset purchase agreement with PTC Therapeuti | Aug 28, 2026 |
| APTN | S-1 | neutral | 3/10 | Adaptin Bio filed an S-1 registration statement to register 382,400 shares of common stock and 38,240 shares underlying | Aug 28, 2026 |
| CPIX | 8-K | bearish | 5/10 | Cumberland Pharmaceuticals disclosed that long-term safety and efficacy data from the open-label extension of its Phase | Aug 28, 2026 |
| OGEN | 8-K | bearish | 7/10 | Oragenics received a delisting notice from NYSE American on August 26, 2026, for failing to meet stockholders' equity re | Aug 28, 2026 |
| MRK | COURT-RULING | neutral | 1/10 | This is a routine procedural order granting an attorney's application to appear pro hac vice in a pending case (Kaiser F | Aug 28, 2026 |
| PHGE | 8-K | neutral | 4/10 | BiomX Inc. announced a 1-for-10 reverse stock split, approved by stockholders on August 25, 2026, effective September 9, | Aug 28, 2026 |
| SPRO | S-3 | bearish | 7/10 | Spero Therapeutics filed a universal shelf registration statement (S-3) to register up to $300M in securities, including | Aug 28, 2026 |
| SBFM | 8-K | neutral | 2/10 | Director Dr. Andrew Keller notified Sunshine Biopharma that he will not seek reelection upon expiration of his current t | Aug 28, 2026 |
| INDV | S-4 | neutral | 6/10 | Indivior Pharmaceuticals filed an S-4 registration statement for an all-stock merger of equals with Supernus Pharmaceuti | Aug 28, 2026 |
| SXTC | 6-K | bearish | 8/10 | China SXT Pharmaceuticals amended its securities purchase agreement with Smart Mart Limited to reset the floor price fro | Aug 28, 2026 |
| ETON | CLUSTER | neutral | 4/10 | Two Eton insiders, including the Chief Business Officer and a Director, sold a combined $2.44M in open-market sales over | Aug 28, 2026 |
| CSBR | DEFA14A | neutral | 2/10 | Champions Oncology filed a DEFA14A notice of internet availability of proxy materials for its 2026 annual meeting. The m | Aug 28, 2026 |
| CRSP | PRESS-RELEASE | bullish | 7/10 | CRISPR Therapeutics presented one-year durability data from its Phase 1a trial of CTX310, an in vivo CRISPR/Cas9 gene ed | Aug 28, 2026 |
| QNRX | 8-K | mixed | 6/10 | Quoin Pharmaceuticals announced a $50M private placement (PIPE) of ADSs and warrants, including insider participation, a | Aug 28, 2026 |
| BAK | 6-K | bearish | 8/10 | Braskem S.A. filed a 6-K reporting that a Brazilian court granted the processing of its extrajudicial reorganization pro | Aug 28, 2026 |
| CYTK | 8-K | bullish | 7/10 | Cytokinetics announced positive Phase 3 results from ACACIA-HCM, the first-ever successful trial in non-obstructive HCM. | Aug 28, 2026 |
| PLUR | 424B5 | bearish | 7/10 | Pluri Inc. is conducting a dilutive registered direct offering of 1.2M common shares and pre-funded warrants for up to 1 | Aug 28, 2026 |
| ATHE | 20-F | neutral | 4/10 | Alterity Therapeutics filed its annual report (20-F) for the fiscal year ended June 30, 2026, reporting an operating los | Aug 28, 2026 |
| BGM | 6-K | bearish | 7/10 | BGM Group Ltd. reported H1 FY2026 (six months ended March 31, 2026) results showing a 70% YoY revenue increase to $24.3M | Aug 28, 2026 |
| BNTX | 6-K | bearish | 6/10 | BioNTech announced termination of the Phase 2 trial (BNT122-01) of autogene cevumeran as monotherapy in resected colorec | Aug 28, 2026 |
| APRE | 8-K | neutral | 2/10 | Aprea Therapeutics issued a press release on August 28, 2026, announcing an expansion of its intellectual property portf | Aug 28, 2026 |
| VVOS | PRESS-RELEASE | neutral | 4/10 | Vivos Therapeutics announced definitive agreements with South Palm Cardiovascular Associates to form AIM Florida, a phys | Aug 28, 2026 |
| IBIO | 8-K | neutral | 4/10 | iBio reported fiscal year 2026 (FYE June 30) results: revenue of $0.1M (down from $0.4M YoY) and a net loss of $33.0M (v | Aug 28, 2026 |
| AMRN | PRESS-RELEASE | neutral | 4/10 | Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly adherent patients on icos | Aug 28, 2026 |
| BLRX | 6-K | bearish | 6/10 | BioLineRx announced a $3.75 million registered direct offering and concurrent private placement, issuing 1,348,921 ADSs | Aug 28, 2026 |